United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $325.45, for a total value of $1,171,620.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $42,308.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
United Therapeutics Stock Up 0.1 %
NASDAQ:UTHR traded up $0.27 during trading hours on Wednesday, hitting $322.23. The company’s stock had a trading volume of 343,222 shares, compared to its average volume of 495,200. The company has a current ratio of 4.35, a quick ratio of 3.64 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $343.98. The stock has a market capitalization of $14.29 billion, a P/E ratio of 15.22, a price-to-earnings-growth ratio of 1.06 and a beta of 0.55. The stock has a fifty day moving average of $310.44 and a 200-day moving average of $263.02.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. During the same quarter in the prior year, the company earned $5.24 EPS. The business’s revenue was up 19.8% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics Co. will post 25.4 earnings per share for the current year.
Analyst Ratings Changes
Check Out Our Latest Analysis on United Therapeutics
Hedge Funds Weigh In On United Therapeutics
Several large investors have recently bought and sold shares of UTHR. Norges Bank acquired a new position in United Therapeutics in the fourth quarter valued at $100,519,000. LSV Asset Management boosted its stake in shares of United Therapeutics by 82.5% during the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after buying an additional 436,851 shares during the period. Swedbank AB acquired a new stake in shares of United Therapeutics during the first quarter worth about $97,316,000. Nordea Investment Management AB boosted its stake in shares of United Therapeutics by 677.6% during the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after buying an additional 262,222 shares during the period. Finally, Avidity Partners Management LP purchased a new position in United Therapeutics during the fourth quarter worth about $52,158,000. Institutional investors and hedge funds own 94.08% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Articles
- Five stocks we like better than United Therapeutics
- Upcoming IPO Stock Lockup Period, Explained
- What Are Bonds? A High-Level Overview
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.